ERBB2 and metastatic malignant neoplasm in the lymph nodes: One of the important differences between subtypes as regards clinical progression is that hormone receptor-positive tumors, such as Luminal A, have a better prognosis for survival compared with Her2 overexpression and TN subtypes (4, 5) and the lowest risk of lymph node metastasis, whereas the Luminal-Her2+ subtype has the highest risk (6).